Tirzepatide
Mounjaro, Zepbound, LY3298176
A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Not Yet Recruiting
PHASE3
NCT07154719
GLP-1R Actions on Muscle and the Skeleton
Pennington Biomedical Research Center
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2, PHASE3
NCT07223242
Tailored Exercise Training Study Among Adults With HFpEF
University of Texas Southwestern Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06345066
A Study of LY3841136 in Overweight and Obese Participants
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04093752
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT06533527
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
The Cleveland Clinic
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE4
NCT07191873
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06901245
Tirzepatide in PWS, HO and GNSO
Grace Kim
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06745128
Tirzepatide for Obesity and Meth Use Disorder
University of Texas Southwestern Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT07091734
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
University of Michigan
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06965413
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Hoffmann-La Roche
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04847557
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE2
NCT06515418
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
BioAge Labs, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06605703
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
Michelle Cardel, PhD, MS, RD
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT07228741
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
St. Jude Children's Research Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
NA
NCT05990374
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
Nanjing First Hospital, Nanjing Medical University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05822830
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NCT06856928
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
University of Colorado, Denver
OBSERVATIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NA
NCT06301256
Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa
Florida Academic Centers Research and Education, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE1
NCT06297616
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06937086
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025